Gilead Sciences Inc
- All
- News
-
Nations Eyeing Gilead's Covid Drug Should Take Note Of Failed Trial: WHO
Health officials reviewing Gilead Science Inc's remdesivir against COVID-19 should consider all evidence, including a trial in which the medicine failed, before giving it the green light, the top WHO scientist said on Friday.
-
Remdesivir Didn't Cut Hospital Stay Or Mortality In Covid Patients: WHO
Gilead Sciences Inc's remdesivir had little or no effect on COVID-19 patients' length of hospital stay or chances of survival, a clinical trial by the World Health Organization (WHO) has found.
-
Gilead Seeks US Approval For Drug That Shortens Covid Recovery Time
Gilead Sciences Inc has filed an application with the U.S. Food and Drug Administration seeking full approval for remdesivir, its experimental COVID-19 drug currently used under emergency authorization, the drugmaker said on Monday.
-
Gilead Analysis Shows Remdesivir Reduced Coronavirus Death Risk
Gilead Sciences Inc said on Friday an analysis showed its antiviral remdesivir helped reduce the risk of death in severely ill COVID-19 patients, but cautioned that rigorous clinical trials were needed to confirm the benefit.
-
Mylan Pharma To Launch Remdesivir In India At Rs 4,800 Per 100 mg Vial
Drugmaker Mylan NV said on Monday it would launch its generic version of Gilead Sciences Inc's COVID-19 treatment remdesivir in India this month at 4,800 rupees ($64.31) per 100 mg vial, as infections surge in the world's third worst-hit country.
-
Gilead Prices COVID-19 Drug Remdesivir At $2,340 Per Patient In Developed Nations
Gilead Sciences Inc on Monday priced its COVID-19 antiviral remdesivir at $2,340 per patient for wealthier nations and agreed to send nearly all of its supply of the drug to the United States over the next three months.
-
US Group Raises Pricing Recommendation For Gilead's Remdesivir In COVID
Gilead Sciences Inc's antiviral remdesivir could be priced up to $5,080 per course based on benefits shown in COVID-19 patients, a U.S. drug pricing research group suggested on Wednesday, above its prior recommendation of around $4,500.
-
US Pharma Firm Gilead To Make 2 Million Courses Of Remdesivir By 2020 End
Gilead Sciences Inc is planning to make more than two million courses of its potential COVID-19 drug remdesivir by the end of the year and start trials of an easier-to-use inhaled version in August, the company said on Monday.
-
Gilead's Drug Prevents Lung Damage In COVID-19 Study On Monkeys: Report
Gilead Sciences Inc's antiviral drug, remdesivir, prevented lung disease in macaque monkeys infected with the new coronavirus, a study published in medical journal Nature showed on Tuesday.
-
India Approves Emergency Use Of Remdesivir To Treat COVID-19 Patients
The government said on Tuesday it has approved Gilead Sciences Inc's antiviral drug remdesivir for emergency use in treating COVID-19 patients.
-
Gilead's Remdesivir Shows Fair Improvement In Moderate COVID-19 Patients
Gilead Sciences Inc on Monday reported that its antiviral drug remdesivir provided a modest benefit in patients with moderate COVID-19 given a five-day course of the treatment, while those who received the medicine for 10 days in the study did not fare as well.
-
Gilead Trades That Made Millions On COVID-19 Drug News Under Scrutiny
Well-timed trades in Gilead Sciences Inc's options ahead of good news on the biopharmaceutical company's COVID-19 drug treatment may draw regulatory scrutiny, experts said.
-
India's Jubilant Signs Licensing Deal For US Pharma Firm Gilead's COVID-19 Drug
India's Jubilant Life Sciences Ltd said on Tuesday it had signed a non-exclusive licensing agreement for selling Gilead Sciences Inc's experimental COVID-19 treatment remdesivir in 127 countries, including India.
-
Gilead Says In Talks With Drugmakers In India, Pak For Making Remdesivir
Gilead Sciences Inc said on Tuesday it was in discussions with chemical and drug manufacturers to produce its experimental COVID-19 drug remdesivir for Europe, Asia and the developing world through at least 2022.
-
What New Data Say About Gilead's Experimental Coronavirus Drug
New clinical data on Gilead Sciences Inc's experimental antiviral drug remdesivir has raised hopes it might be an effective treatment for the novel coronavirus that has infected more than 3 million people and killed over 225,000 worldwide.
-
Nations Eyeing Gilead's Covid Drug Should Take Note Of Failed Trial: WHO
Health officials reviewing Gilead Science Inc's remdesivir against COVID-19 should consider all evidence, including a trial in which the medicine failed, before giving it the green light, the top WHO scientist said on Friday.
-
Remdesivir Didn't Cut Hospital Stay Or Mortality In Covid Patients: WHO
Gilead Sciences Inc's remdesivir had little or no effect on COVID-19 patients' length of hospital stay or chances of survival, a clinical trial by the World Health Organization (WHO) has found.
-
Gilead Seeks US Approval For Drug That Shortens Covid Recovery Time
Gilead Sciences Inc has filed an application with the U.S. Food and Drug Administration seeking full approval for remdesivir, its experimental COVID-19 drug currently used under emergency authorization, the drugmaker said on Monday.
-
Gilead Analysis Shows Remdesivir Reduced Coronavirus Death Risk
Gilead Sciences Inc said on Friday an analysis showed its antiviral remdesivir helped reduce the risk of death in severely ill COVID-19 patients, but cautioned that rigorous clinical trials were needed to confirm the benefit.
-
Mylan Pharma To Launch Remdesivir In India At Rs 4,800 Per 100 mg Vial
Drugmaker Mylan NV said on Monday it would launch its generic version of Gilead Sciences Inc's COVID-19 treatment remdesivir in India this month at 4,800 rupees ($64.31) per 100 mg vial, as infections surge in the world's third worst-hit country.
-
Gilead Prices COVID-19 Drug Remdesivir At $2,340 Per Patient In Developed Nations
Gilead Sciences Inc on Monday priced its COVID-19 antiviral remdesivir at $2,340 per patient for wealthier nations and agreed to send nearly all of its supply of the drug to the United States over the next three months.
-
US Group Raises Pricing Recommendation For Gilead's Remdesivir In COVID
Gilead Sciences Inc's antiviral remdesivir could be priced up to $5,080 per course based on benefits shown in COVID-19 patients, a U.S. drug pricing research group suggested on Wednesday, above its prior recommendation of around $4,500.
-
US Pharma Firm Gilead To Make 2 Million Courses Of Remdesivir By 2020 End
Gilead Sciences Inc is planning to make more than two million courses of its potential COVID-19 drug remdesivir by the end of the year and start trials of an easier-to-use inhaled version in August, the company said on Monday.
-
Gilead's Drug Prevents Lung Damage In COVID-19 Study On Monkeys: Report
Gilead Sciences Inc's antiviral drug, remdesivir, prevented lung disease in macaque monkeys infected with the new coronavirus, a study published in medical journal Nature showed on Tuesday.
-
India Approves Emergency Use Of Remdesivir To Treat COVID-19 Patients
The government said on Tuesday it has approved Gilead Sciences Inc's antiviral drug remdesivir for emergency use in treating COVID-19 patients.
-
Gilead's Remdesivir Shows Fair Improvement In Moderate COVID-19 Patients
Gilead Sciences Inc on Monday reported that its antiviral drug remdesivir provided a modest benefit in patients with moderate COVID-19 given a five-day course of the treatment, while those who received the medicine for 10 days in the study did not fare as well.
-
Gilead Trades That Made Millions On COVID-19 Drug News Under Scrutiny
Well-timed trades in Gilead Sciences Inc's options ahead of good news on the biopharmaceutical company's COVID-19 drug treatment may draw regulatory scrutiny, experts said.
-
India's Jubilant Signs Licensing Deal For US Pharma Firm Gilead's COVID-19 Drug
India's Jubilant Life Sciences Ltd said on Tuesday it had signed a non-exclusive licensing agreement for selling Gilead Sciences Inc's experimental COVID-19 treatment remdesivir in 127 countries, including India.
-
Gilead Says In Talks With Drugmakers In India, Pak For Making Remdesivir
Gilead Sciences Inc said on Tuesday it was in discussions with chemical and drug manufacturers to produce its experimental COVID-19 drug remdesivir for Europe, Asia and the developing world through at least 2022.
-
What New Data Say About Gilead's Experimental Coronavirus Drug
New clinical data on Gilead Sciences Inc's experimental antiviral drug remdesivir has raised hopes it might be an effective treatment for the novel coronavirus that has infected more than 3 million people and killed over 225,000 worldwide.
